Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Sage Therapeutics is doubling down on the “blockbuster potential” of its postpartum depression drug Zurzuvae, expanding professional promotions and taking steps toward a direct-to-consumer launch after a series of disappointments.
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
Sage Therapeutics to Present at Upcoming March Investor Conferences
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Sage Therapeutics and Biogen may not have the broad label that they had hoped for with Zurzuvae, but the two companies are still touting the med’s initial launch performance in postpartum depression (PPD).
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
Two months ago, in presenting quarterly earnings, CEO Barry Greene said Sage Therapeutics was on its way to becoming a “leaner and stronger company.”
Sage Therapeutics Announces Changes to Board of Directors